S Cascinu

Summary

Publications

  1. ncbi request reprint New target therapies in advanced pancreatic cancer
    S Cascinu
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Ancona, Italy
    Ann Oncol 17:v148-52. 2006
  2. ncbi request reprint Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
    Stefano Cascinu
    Polytechnic University of Marche Riuniti Hospital Umberto I GM Lancisi G Salesi of Ancona, 60020 Ancona, Italy
    Lancet Oncol 9:39-44. 2008
  3. ncbi request reprint Gastrointestinal cancer refractory to chemotherapy: a role for octreotide?
    S Cascinu
    Section of Experimental Oncology, Division of Medical Oncology, Azienda Ospedaliera S Salvatore, Pesaro, Italy
    Chemotherapy 47:127-33. 2001
  4. ncbi request reprint Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial
    Stefano Cascinu
    Department of Medical Oncology, Azienda Ospedaliera Universitaria di Parma, Via Gramsci 14, 43100 Parma, Italy
    J Clin Oncol 20:3478-83. 2002
  5. ncbi request reprint P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II study
    Giorgio Cocconi
    Medical Oncology Division, Azienda Ospedaliera Universitaria, Parma, Italy
    Am J Clin Oncol 26:535-42. 2003
  6. doi request reprint Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study
    Stefano Cascinu
    Medical Oncology Unit, Universita Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy Electronic address
    Dig Liver Dis 46:182-6. 2014
  7. pmc Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Marche Via Conca, Ancona, 60020, Italy
    J Transl Med 10:71. 2012
  8. pmc Role of maspin in cancer
    Rossana Berardi
    Medical Oncology Unit, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi di Ancona, Via Conca, Ancona, 71 60126, Italy
    Clin Transl Med 2:8. 2013
  9. pmc Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
    J Exp Clin Cancer Res 29:164. 2010
  10. pmc Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    BMC Cancer 9:303. 2009

Detail Information

Publications145 found, 100 shown here

  1. ncbi request reprint New target therapies in advanced pancreatic cancer
    S Cascinu
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Ancona, Italy
    Ann Oncol 17:v148-52. 2006
    ..This review highlights recent findings in the treatment of pancreatic cancer by using these novel therapeutic approaches...
  2. ncbi request reprint Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
    Stefano Cascinu
    Polytechnic University of Marche Riuniti Hospital Umberto I GM Lancisi G Salesi of Ancona, 60020 Ancona, Italy
    Lancet Oncol 9:39-44. 2008
    ..The aim of this study was to assess the activity and feasibility of a combination of cetuximab with gemcitabine and cisplatin compared with use of gemcitabine and cisplatin alone for the treatment of advanced pancreatic cancer...
  3. ncbi request reprint Gastrointestinal cancer refractory to chemotherapy: a role for octreotide?
    S Cascinu
    Section of Experimental Oncology, Division of Medical Oncology, Azienda Ospedaliera S Salvatore, Pesaro, Italy
    Chemotherapy 47:127-33. 2001
    ....
  4. ncbi request reprint Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial
    Stefano Cascinu
    Department of Medical Oncology, Azienda Ospedaliera Universitaria di Parma, Via Gramsci 14, 43100 Parma, Italy
    J Clin Oncol 20:3478-83. 2002
    ..We performed a randomized, double-blind, placebo-controlled trial to assess the efficacy of glutathione (GSH) in the prevention of oxaliplatin-induced neurotoxicity...
  5. ncbi request reprint P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II study
    Giorgio Cocconi
    Medical Oncology Division, Azienda Ospedaliera Universitaria, Parma, Italy
    Am J Clin Oncol 26:535-42. 2003
    ..It is feasible and warrants further research, which would ideally take the form of a randomized comparison of P-CHOP and CHOP, possibly with the addition of rituximab in both arms...
  6. doi request reprint Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study
    Stefano Cascinu
    Medical Oncology Unit, Universita Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy Electronic address
    Dig Liver Dis 46:182-6. 2014
    ..A phase II randomized trial was designed to investigate the activity of sorafenib in combination with chemotherapy in advanced pancreatic cancer...
  7. pmc Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Marche Via Conca, Ancona, 60020, Italy
    J Transl Med 10:71. 2012
    ..The EGFR pathway activation via the Ras-Raf-MAP-kinase and the protein-serine/threonine kinase AKT could determine resistance to anti-EGFR treatment...
  8. pmc Role of maspin in cancer
    Rossana Berardi
    Medical Oncology Unit, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi di Ancona, Via Conca, Ancona, 71 60126, Italy
    Clin Transl Med 2:8. 2013
    ..Further studies in these directions are necessary to better define the therapeutic implication of maspin...
  9. pmc Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
    J Exp Clin Cancer Res 29:164. 2010
    ..In our experience, lipiodol TACE showed a better OS and TTP over pTACE, without difference in toxicity profile and RR. Among the staging systems analyzed only the Okuda stage seemed able to reliably predict patients outcome...
  10. pmc Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    BMC Cancer 9:303. 2009
    ..Based on these findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab...
  11. ncbi request reprint Molecular markers predictive of response to chemotherapy in gastrointestinal tumors
    V Catalano
    Department of Medical Oncology, Azienda Ospedaliera Ospedale S Salvatore, 61100, Pesaro, Italy
    Crit Rev Oncol Hematol 38:93-104. 2001
    ..Available data are promising, but most of them arise from retrospective and small studies. Well designed, prospective trials are warranted to change the target approach from a general to an individual treatment strategy...
  12. ncbi request reprint Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy
    S Cascinu
    Medical Oncology, Hospital of Parma, Italy
    Ann Oncol 12:239-44. 2001
    ..The combined analysis of SPF/VEGF was studied for predictivity of recurrent disease, the TS quantitation was related to the efficacy of fluorouracil-based adjuvant chemotherapy...
  13. ncbi request reprint Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients
    S Cascinu
    Sezione di Oncologia Sperimentale, Azienda Ospedaliera Ospedale S Salvatore, 61100 Pesaro, Italy
    Cancer Invest 19:8-12. 2001
    ....
  14. ncbi request reprint Pain and its treatment in hospitalized patients with metastatic cancer
    Stefano Cascinu
    Medical Oncology, University Hospital of Parma, Parma, Italy
    Support Care Cancer 11:587-92. 2003
    ..The aim of this prospective study was to assess the quality of pain management hospitalized cancer patients...
  15. ncbi request reprint A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
    S Cascinu
    Medical Oncology, Azienda Ospedaliera di Parma, Italy
    Ann Oncol 11:1309-11. 2000
    ..Laboratory evidences suggest the possibility that an infusion rate of 10 mg/m2/min may be more effective than the standard 30-min infusion of Gemcitabine (GEM)...
  16. ncbi request reprint Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination
    S Cascinu
    Department of Medical Oncology, Azienda Ospedaliera di Parma, Italy
    Ann Oncol 11:1053-6. 2000
    ..We assessed the hypothesis that a compromised p53 function could account for the non response of colon cancer patients with low thymidylate synthase (TS) expression receiving a bolus 5-fluorouracil (5-FU) leucovorin (LV) combination...
  17. ncbi request reprint Survival and quality of life in gastrointestinal tumors: two different end points?
    S Cascinu
    Medical Department, Azienda Ospedaliera di Parma, Italy
    Ann Oncol 12:S31-6. 2001
    ..In gastrointestinal tumors, the traditional end point of medical treatment was represented mainly by survival. In the last few years, however, there has been an increasing awareness about the role of quality of life...
  18. ncbi request reprint Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors
    S Cascinu
    Department of Medical Oncology, Azienda Ospedaliera di Parma, Italy
    Clin Exp Metastasis 18:651-5. 2000
    ..Evidence is supported that the VEGF expression may be different between colon cancer metastatic sites. The efficacy of anti-VEGF treatments may depend on the VEGF expression status, and this finding deserves further investigation...
  19. pmc Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen
    S Cascinu
    Department of Medical Oncology, V le Gramsci 14, 43100 Parma, Italy
    Br J Cancer 86:213-7. 2002
    ..Because of its low cost it may be suggested for patients not enrolled into clinical trials...
  20. pmc An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation
    S Cascinu
    Division of Medical Oncology, Hospital of Parma, Italy
    Br J Cancer 86:744-9. 2002
    ..In this study, vascular endothelial growth factor and p53 expressions correlated with recurrent disease, pattern of relapse and poor event-free survival...
  21. ncbi request reprint Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)
    S Cascinu
    Department of Medical Oncology, Azienda Ospedaliera di Parma, Italy
    Ann Oncol 13:716-20. 2002
    ..To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin combination (TOMOX) as first-line chemotherapy for patients with advanced colorectal cancer...
  22. pmc High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract
    S Cascinu
    Clinica di Oncologia, Università Politecnica delle Marche Azienda Ospedaliera Umberto I, Via Conca, Ancona 60020, Italy
    Br J Cancer 90:1521-5. 2004
    ..The median and 4-year survival for the whole group was 17 months and 31%, respectively. The median survival was 12 months for inoperable patients and it was not reached in resected patients...
  23. ncbi request reprint Gastric cancer treatment: a systematic review
    Rossana Berardi
    Clinica di Oncologia Medica, Università Politecnica delle Marche Azienda Ospedaliera Umberto I, 60020 Ancona, Italy
    Oncol Rep 11:911-6. 2004
    ..This review will focus on the several treatment modalities available for gastric cancer patients: surgery, adjuvant, neoadjuvant and palliative chemotherapy as well as new target agents...
  24. ncbi request reprint Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer
    S Cascinu
    Istituto di Oncologia, Universita degli Studi di Messina, Italy
    Clin Cancer Res 6:2803-7. 2000
    ..66 +/- 0.17; P = 0.0001). VEGF may be used in a clinical setting to identify patients at high risk for relapse who may benefit from adjuvant treatment including new therapeutic strategies such as monoclonal antibody neutralizing VEGF...
  25. ncbi request reprint Effects of calcium and vitamin supplementation on colon cell proliferation in colorectal cancer
    S Cascinu
    Section of Experimental Oncology, Azienda Ospedaliera S Salvatore, Pesaro, Italy
    Cancer Invest 18:411-6. 2000
    ..Furthermore, this study suggests the need for extreme caution in the interpretation and publication of studies on chemoprotectants in colon cancer without a control group...
  26. doi request reprint Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial
    Stefano Cascinu
    Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 60020 Ancona, Italy
    Cancer Chemother Pharmacol 68:37-43. 2011
    ..With the aim to maintain efficacy while reducing toxicity, we compared the activity and safety of a combination of 5-FU, cisplatin and pegylated liposomal doxorubicin with a combination of 5-FU, cisplatin and mitomycin-C...
  27. ncbi request reprint COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin
    Stefano Cascinu
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda ospedaliera Ospedali Riuniti Umberto I, Lancisi, Salesi, Ancona, Italy
    Am J Clin Oncol 30:526-30. 2007
    ..We investigated the role of COX-2 and NF-KB expression in relation to the use of a COX-2 inhibitor (celecoxib) associated to gemcitabine and oxaliplatin in pancreatic cancer...
  28. ncbi request reprint Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial
    Stefano Cascinu
    Universita Politecnica delle Marche, Via Conca 60020 Ancona, Italy
    J Natl Cancer Inst 99:601-7. 2007
    ....
  29. ncbi request reprint A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
    S Cascinu
    Department of Medical Oncology, University of Messina, Italy
    Ann Oncol 10:1377-9. 1999
    ..We determined the maximum tolerable dose of docetaxel combined with a weekly fixed dose of gemcitabine and assessed the activity of this combination in advanced pancreatic cancer...
  30. pmc A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation
    S Cascinu
    Department of Medical Oncology, Universita Politecnica delle Marche, Ancona, Italy
    Br J Cancer 98:71-6. 2008
    ..Furthermore, while NF-kB activation seems to predict resistance to chemotherapy as demonstrated 'in vitro' models, gefitinib does not overcome this mechanism of resistance, as reported for cetuximab...
  31. ncbi request reprint Resection-line involvement in gastric cancer patients undergoing curative resections: implications for clinical management
    S Cascinu
    Division of Medical Oncology, Azienda Ospedaliera Ospedale S Salvatore, Pesaro, Italy
    Jpn J Clin Oncol 29:291-3. 1999
    ..Resection-line involvement has been suggested as an important prognostic factor for gastric cancer...
  32. pmc A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer
    S Cascinu
    Division of Medical Oncology, Azienda Ospedale di Parma, Italy
    Br J Cancer 84:470-4. 2001
    ..The sequential application of docetaxel after PELF chemotherapy gained major objective responses with manageable toxicity. This strategy is worth of further investigation in the setting of palliative or neoadjuvant chemotherapy...
  33. pmc Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
    S Cascinu
    Department of Medical Oncology, Ancona, Italy
    Br J Cancer 79:491-4. 1999
    ..7%) and of thrombocytopenia in 3 out of 188 cycles (1.5%). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in pancreatic cancer...
  34. ncbi request reprint Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil
    C Aschele
    Department of Medical Oncology, EO Ospedali Galliera, Genoa, Italy
    Ann Oncol 13:1882-92. 2002
    ....
  35. ncbi request reprint The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients
    M Scartozzi
    Clinica di Oncologia Medica, Azienda Ospedaliera Umberto I Università Politecnica delle Marche, Ancona, Italy
    Oncology 68:212-6. 2005
    ....
  36. pmc Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
    S Cascinu
    Division of Medical Oncology, S Salvatore Hospital, Pesaro, Italy
    Br J Cancer 78:390-3. 1998
    ..This weekly intensive regimen enabled resection in half of previously inoperable tumours with a moderate toxicity. It can be offered to patients with locally advanced unresectable gastric cancer to obtain curative resection...
  37. pmc A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Italy
    Br J Cancer 89:1428-32. 2003
    ..The weekly PLF regimen resulted safe and effective in elderly patients with advanced GC. This outpatient regimen is based on old and low-cost drugs and it may represent an alternative to new and more expensive combinations...
  38. pmc Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients
    M Scartozzi
    The Departments of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, , Via Conca, 60020 Ancona, Italy
    Br J Cancer 95:445-9. 2006
    ....
  39. doi request reprint Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
    M Scartozzi
    Clinic of Medical Oncology, Polytechnic University of the Marche Region, Riuniti Hospital, Ancona, Italy
    Ann Oncol 20:227-30. 2009
    ....
  40. doi request reprint Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab
    M Scartozzi
    Department of Medical Oncology, United Hospitals, and Postgraduate School in Medical Oncology, University of Ancona, Ancona, Italy
    Ann Oncol 23:1706-12. 2012
    ....
  41. ncbi request reprint Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy
    F Graziano
    University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Expert Rev Anticancer Ther 1:247-57. 2001
    ..High-risk patients could be the target for future adjuvant chemotherapy trials and one or more of these markers may identify prognostic subgroups with the same TNM stage category...
  42. ncbi request reprint A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Italy
    Ann Oncol 11:1263-6. 2000
    ..In this study, we explored the activity of weekly docetaxel in patients with advanced gastric cancer who failed first-line chemotherapy...
  43. ncbi request reprint A pilot clinical trial of postoperative intensive weekly chemotherapy using cisplatin, epi-doxorubicin, 5-fluorouracil, 6S-leucovorin, glutathione and filgrastim in patients with resected gastric cancer
    F Graziano
    Section of Experimental Oncology, Ospedale S. Salvatore, Pesaro, Italy
    Tumori 84:368-71. 1998
    ..These data, together with recent results in advanced disease, make this approach of interest for the development of new programs of adjuvant therapy in this setting...
  44. pmc Over-DI dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients
    M Scartozzi
    Department of Medical Oncology, , Ancona, Italy
    Br J Cancer 92:1051-4. 2005
    ..An inadequate lymph nodes resection can affect survival and result in a higher incidence of local relapse, making the latter group of patients optimal candidates for adjuvant chemoradiation...
  45. ncbi request reprint Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination
    S Cascinu
    Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
    J Chemother 4:46-9. 1992
    ..We conclude that salvage chemotherapy is not recommended in colorectal cancer after 5-fluorouracil/leucovorin treatment even in patients with generally considered favorable characteristics for response to chemotherapy...
  46. pmc Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Italy
    BMC Cancer 1:9. 2001
    ..According to this hypothesis, we investigated the p53 and the DCC proteins expression in different stages of gastric carcinomas...
  47. pmc Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
    C Pinto
    Department of Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Br J Cancer 101:1261-8. 2009
    ..The purpose of this phase II study was to evaluate the activity and safety of cetuximab combined with cisplatin and docetaxel as a first-line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma...
  48. ncbi request reprint Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors
    S Cascinu
    Azienda Ospedaliera di Parma, Parma, Italy
    Ann Oncol 14:ii25-9. 2003
    ....
  49. pmc Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial
    D Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    BMC Cancer 6:125. 2006
    ..The secondary objective was to measure the time to disease progression and the survival time...
  50. pmc Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
    M Scartozzi
    Department of Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020 Ancona, Italy
    Br J Cancer 104:1786-90. 2011
    ..The primary aim of our study was to verify a possible correlation between EGFR gene promoter methylation and clinical outcome in metastatic colorectal cancer patients receiving chemotherapy with irinotecan and cetuximab...
  51. pmc VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
    M Scartozzi
    Department of Clinical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy
    Br J Cancer 108:1126-32. 2013
    ..We assessed the role of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) polymorphisms in the prediction of the clinical outcome in metastatic renal cell carcinoma (mRCC) patients...
  52. ncbi request reprint A pilot clinical trial of surgical adjuvant treatment with high-dose 6S-leucovorin/5-fluorouracil and radiation therapy for high-risk rectal carcinoma
    S Cascinu
    Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
    Tumori 80:335-8. 1994
    ..The advantage of this combination, in terms of recurrence rate and survival with respect to 5FU/radiotherapy alone, will have to be evaluated in randomized trials...
  53. pmc A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
    S Cascinu
    Division of Medical Oncology, Azienda Ospedaliera Ospedale S Salvatore, Pesaro, Italy
    Br J Cancer 80:1595-8. 1999
    ....
  54. pmc Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
    M Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, Ancona, Italy
    Br J Cancer 106:799-804. 2012
    ..We explored the role of pre-treatment LDH serum levels in colorectal cancer patients receiving first-line bevacizumab...
  55. doi request reprint Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients
    C Braconi
    Centro Regionale di Genetica Oncologica Oncologia Medica, Universita Politecnica delle Marche, Ancona, Italy
    Ann Oncol 19:1293-8. 2008
    ..The expression of the insulin-like growth factor (IGF) system has never been studied in gastrointestinal stromal tumors (GISTs)...
  56. ncbi request reprint Treatment of elderly advanced gastric cancer patients with 5-fluorouracil and leucovorin combination
    S Cascinu
    Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
    J Chemother 4:185-8. 1992
    ..Because of this we think that this regimen cannot be recommended for the treatment of elderly advanced gastric cancer patients...
  57. ncbi request reprint Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Urbino, Italy
    Ann Oncol 14:1026-38. 2003
    ..Markers of altered DCC function have shown promising prognostic role and sufficient prevalence in retrospective investigations and they deserve further assessment in prospective studies...
  58. ncbi request reprint Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Italy
    Ann Oncol 15:489-92. 2004
    ..In this perspective, we investigated E-cadherin gene (CDH1) promoter hypermethylation in gastric carcinomas and its correlation with E-cadherin protein expression...
  59. ncbi request reprint Pre-operative treatment modalities in gastric cancer patients
    M Scartozzi
    Clinica di Oncologia Medica, Università Politecnica delle Marche Azienda Ospedaliera Ospedali Riuniti, via Conca 60 020, Ancona, Italy
    Ann Oncol 16:iv106-109. 2005
  60. ncbi request reprint 5-Fluorouracil dose intensity increase in 5-fluorouracil and leucovorin combination: results of a phase II study
    S Cascinu
    Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
    J Chemother 3:51-4. 1991
    ..Furthermore, in an analysis of data from the literature we did not find any difference in response rate in relation to dose intensity in the 5-fluorouracil/leucovorin combination...
  61. ncbi request reprint Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
    C Pinto
    Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Ann Oncol 18:510-7. 2007
    ..The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma...
  62. ncbi request reprint Intensive weekly chemotherapy for elderly gastric cancer patients, using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and glutathione with the support of G-CSF
    S Cascinu
    Servizio di Oncologia Medica, Ospedali Riuniti, Pesaro, Italy
    Tumori 81:32-5. 1995
    ..CONCLUSIONS: This regimen appears feasible also in elderly gastric cancer patients and, because of its activity, suitable for further studies...
  63. ncbi request reprint Feasibility of preoperative chemoradiation in rectal cancer patients aged 70 and older
    G Mantello
    Dept of Oncology and Radiotherapy, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy
    J Exp Clin Cancer Res 24:541-6. 2005
    ..In conclusion, concomitant radiochemotherapy 5FU based is safe in rectal cancer patients aged > or = 70 with a good tumour downstaging (61% of patients) and excellent feasibility. No treatment related death was observed...
  64. pmc Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
    M Scartozzi
    Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti Università Politecnica delle Marche, Via Conca 60020, Ancona, Italy
    Br J Cancer 97:92-7. 2007
    ..EGFR downstream signalling pathway can be overactivated even in the absence of EGFR expression in a considerable proportion of patients...
  65. doi request reprint Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients
    M Scartozzi
    Department of Medical Oncology, United Hospitals, Polytechnic Marche University, Ancona, Italy
    Ann Oncol 22:897-902. 2011
    ..Preclinical studies suggested that integrins are relevant for gastric cancer diffusion. We investigated integrins polymorphisms role in determining peritoneal carcinosis or hematogenous metastases in radically resected gastric cancer...
  66. ncbi request reprint A pilot clinical trial of postoperative adjuvant intraperitoneal cisplatin, 5-fluorouracil, 6S-leucovorin and interferon alpha 2b in patients with resected gastric cancer
    S Cascinu
    Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
    Tumori 79:331-5. 1993
    ..These data make this approach interesting for the development of new programs of adjuvant therapy of high-risk gastric cancer...
  67. pmc Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer
    S Cascinu
    Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
    Br J Cancer 69:392-3. 1994
    ....
  68. pmc Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study
    S Cascinu
    Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
    Br J Cancer 67:156-8. 1993
    ..Haemoglobin increases occurred despite continuation of cisplatin chemotherapy. In conclusion subcutaneous low dose of erythropoietin seems to be effective and safe in the treatment of cisplatin-induced anaemia...
  69. ncbi request reprint Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives
    A Bittoni
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    Eur Rev Med Pharmacol Sci 14:309-14. 2010
    ..In advanced disease, major improvements of the last years are represented by the introduction of oral fluoropyrimidines and drugs such as docetaxel or irinotecan and the demonstration of efficacy of the anti-HER2 agent trastuzumab...
  70. ncbi request reprint Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy
    Rossana Berardi
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Unmberto 1, G M Lancisi, G Salesi, Ancona, Italy
    Tumori 91:463-6. 2005
    ..The aim of the present study was to analyze the tolerability and activity of chemotherapy with 5-fluorouracil plus oxaliplatin or CPT-11 in elderly patients with advanced colorectal cancer...
  71. pmc Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells
    M Santoni
    Department of Medical Oncology, Polytechnic University of the Marche Region, 60121 Ancona, Italy
    Br J Cancer 109:1040-50. 2013
    ..Our aim was to evaluate cytotoxic effects induced by sunitinib and pazopanib in 5637 and J82 bladder cancer cell lines...
  72. pmc A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy
    S Cascinu
    Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
    Br J Cancer 71:97-101. 1995
    ..Additional studies will be needed to confirm these results and to clarify other questions about dose and schedule of octreotide...
  73. doi request reprint KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study
    C Braconi
    Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona, Italy
    Ann Oncol 19:706-10. 2008
    ..The prognostic significance of KIT or platelet-derived growth factor receptor alpha (PDGFRalpha) mutations in gastrointestinal stromal tumors (GISTs) is still controversial...
  74. ncbi request reprint Chemotherapy for advanced pancreatic cancer: the history is changing
    F Graziano
    Sezione di Oncologia Sperimentale, Azienda Ospedaliera Ospedale S. Salvatore, Pesaro, Italy
    Tumori 84:308-11. 1998
    ..The results are far from conclusive, and only partially satisfying but they represent a step forward...
  75. ncbi request reprint Different doses of pamidronate in patients with painful osteolytic bone metastases
    S Cascinu
    Sezione di Oncologia Sperimentale, Azienda Ospedaliera Ospedale S Salvatore, Pesaro, Italy
    Support Care Cancer 6:139-43. 1998
    ..In conclusion, our results seem to confirm the utility of higher doses of pamidronate in patients with painful bone metastases, because of the faster symptom relief achieved...
  76. ncbi request reprint Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases
    Stefano Pergolizzi
    Department of Radiological Science, University of Messina, Messina, Italy
    Int J Radiat Oncol Biol Phys 65:25-32. 2006
    ....
  77. ncbi request reprint Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes
    Nicola Battelli
    Clinica di Oncologia Medica, Dipartimento di Oncologia e Radioterapia, Ospedali Riuniti Umberto I G M Lancisi G Salesi, Polo Ospedale Università, Ancona, Italy
    Am J Clin Oncol 29:380-4. 2006
    ....
  78. ncbi request reprint Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer
    Mario Scartozzi
    Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Universita Politecnica delle Marche, Ancona, Italy
    Tumori 92:384-8. 2006
    ..We evaluated the activity in terms of time to progression (TTP) of mitomycin C and capecitabine in patients with advanced colorectal cancer who progressed after 2 lines of chemotherapy...
  79. doi request reprint Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278)
    Valentina Guarneri
    Division of Medical Oncology, Department of Oncology and Hematology, University Hospital, Modena, Italy
    Clin Breast Cancer 8:453-6. 2008
    ..The primary objective is disease-free survival...
  80. ncbi request reprint Adjuvant chemotherapy in gastric cancer. The Italian experience and review of the literature
    Rossana Berardi
    Medical Oncology Department, University of Ancona, Azienda Ospedaliera Umberto I, Ancona, Italy
    Suppl Tumori 2:S45-7. 2003
    ..The aim of the present review is to summarize the results of previously performed randomized trials to evaluate the effects of adjuvant therapy in gastric cancer...
  81. ncbi request reprint Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy
    Mario Scartozzi
    Clinica di Oncologia Medica and Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti, Universita Politecnica delle Marche, Ancona, Italy
    J Clin Oncol 25:3930-5. 2007
    ..The aim of our analysis was to investigate a correlation between NF-kB expression, response rate, time to progression, and survival in advanced colorectal cancer patients receiving cetuximab and irinotecan...
  82. ncbi request reprint Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies
    Mario Scartozzi
    Clinica di Oncologia Medica, Istituto di Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
    J Clin Oncol 22:4772-8. 2004
    ....
  83. ncbi request reprint Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients
    Mario Scartozzi
    Clinica di Oncologia Medica, Azienda Ospedaliero Universitaria Ospedali Riuniti e Università Politecnica delle Marche, Ancona, Italy
    Lung Cancer 53:103-9. 2006
    ..031) and 10 months versus 9 months for hMSH2 (p=0.8330). Both the difference in response rate and in median survival observed according to MMR status seem to confirm what has been suggested by preclinical studies...
  84. ncbi request reprint [The DUR studies: colon cancer adjuvants]
    Stefano Cascinu
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Ancona
    Suppl Tumori 3:S88. 2004
  85. doi request reprint Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcome
    Rossana Berardi
    Medical Oncology Unit, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Ancona, Italy
    Int J Radiat Oncol Biol Phys 75:1437-43. 2009
    ..To determine the importance of downstaging of locally advanced rectal cancer after neoadjuvant treatment...
  86. doi request reprint Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study
    D Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Ann Oncol 23:2072-7. 2012
    ..Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC...
  87. ncbi request reprint Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma
    M Santoni
    Department of Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero Universitaria, Ospedali Riuniti Umberto I GM Lancisi and G Salesi, Ancona, Italy
    Anticancer Res 32:1099-101. 2012
    ..Results indicate that our temozolomide -FTM combined schedule is not effective, although well tolerated, in non responsive patients with GBM. Further strategies are required to improve the outcome of these patients...
  88. ncbi request reprint Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study
    P Lippe
    Department of Medical Oncology, Ancona University, Italy
    Ann Oncol 10:217-21. 1999
    ..However, the optimal schedule for administration of the two drugs has not yet been determined. In this study we evaluated the activity and toxicity of a weekly gemcitabine and cisplatin schedule...
  89. doi request reprint Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan
    Mario Scartozzi
    Department of Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    Int J Cancer 127:1941-7. 2010
    ..Combined IGF-1 and K-RAS analysis may represent an effective strategy for a better selection of responding colorectal cancer patients...
  90. ncbi request reprint Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer
    Mario Scartozzi
    AO Ospedali Riuniti Università Politecnica delle Marche, Clinica di Oncologia Medica, Via Conca, 60020, Ancona, Italy
    Curr Opin Mol Ther 12:361-71. 2010
    ..Although preliminary results appear promising, only future clinical and translational data will clarify the best clinical setting and treatment combinations for the optimal use of dalotuzumab in clinical practice...
  91. ncbi request reprint Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapy
    Filippo Grillo-Ruggieri
    Dipartimento di Oncologia e Radioterapia Generale, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy
    Dis Colon Rectum 50:1594-603. 2007
    ..The aim of this study was to evaluate downstaging as primary end point, and progression-free survival and overall survival as secondary end points, in rectal adenocarcinoma patients treated with preoperative chemoradiation...
  92. doi request reprint Pancreatic cancer: progress in cancer therapy
    Chiara Pierantoni
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, Lancisi, Salesi, Ancona, Italy
    Crit Rev Oncol Hematol 67:27-38. 2008
    ..New treatment strategies and a more careful evaluation of innovative therapies are clearly needed for this disease. In this review we will focus on treatment strategies both in resectable and advanced pancreatic cancer...
  93. ncbi request reprint Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients
    Vittorio Franciosi
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Lung Cancer 41:101-6. 2003
    ..The aims of this phase II study were to evaluate the response rate and toxicity of the gemcitabine-oxaliplatin combination in patients with advanced NSCLC and poor prognosis...
  94. ncbi request reprint Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer
    Mario Scartozzi
    Department of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti Università Politecnica delle Marche, Ancona and Istituto di Anatomia Patologica, Universita Politecnica delle Marche, Ancona, Italy
    Anal Quant Cytol Histol 28:61-8. 2006
    ..Moreover, the biological selection of colorectal tumors more likely to benefit from this treatment approach is still to be defined...
  95. ncbi request reprint New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocols
    Rossana Berardi
    Medical Oncology Unit of the Università Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi and G Salesi di Ancona, Ancona, Italy
    JOP 6:118-21. 2005
  96. ncbi request reprint Compliance and outcomes in locally advanced head and neck cancer patients treated with alternating chemo-radiotherapy in clinical practice
    Vittorio Franciosi
    Division of Medical Oncology, University Hospital of Parma, Italy
    Tumori 89:20-5. 2003
    ..To evaluate the feasibility in clinical practice of alternating chemo-radiotherapy in locally advanced head and neck cancer patients...
  97. ncbi request reprint The role of levamisole in the adjuvant treatment of stage III colon cancer patients: a randomized trial of 5-fluorouracil and levamisole versus 5-fluorouracil alone
    Stefano Cascinu
    Clinica di Oncologia Medica, Universita degli Studi di Ancona, Ospedale di Torrette, 60020 Ancona, Italy
    Cancer Invest 21:701-7. 2003
    ..The addition of Lev to 5FU does not seem to be relevant for the clinical activity of this adjuvant regimen, whereas toxicity related to Lev should be considered when an adjuvant treatment for stage III colon cancer patients is proposed...
  98. ncbi request reprint Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers
    R Berardi
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I Lancisi Salesi, Ancona, Italy
    Lung Cancer 49:371-6. 2005
    ..Our results suggested that anemia could represent an important prognostic factor in resected NSCLC and correction of anemia in the perioperative setting does not reduce the risk of relapse...
  99. ncbi request reprint [Paraneoplastic syndromes: a review]
    R Berardi
    Clinica di Oncologia Medica, Azienda Ospedaliero, Universita Politecnica delle Marche, Ancona, Italia
    Clin Ter 156:281-8. 2005
    ..This review discusses all the main paraneoplastic syndromes, focusing mainly on their clinical aspect and reminding the most commonly associated cancers...
  100. doi request reprint Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Ancona, Universita Politecnica delle Marche, Ancona, Italy
    Cancer Treat Rev 35:451-62. 2009
    ..This systematic review will analyse available data about these factors with the aim to constitute a starting point for future research...
  101. doi request reprint Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2
    Rossana Berardi
    Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi G Salesi di Ancona, Medical Oncology Unit, 60020 Ancona, Italy
    Expert Opin Pharmacother 10:2467-78. 2009
    ..The present review analyzes the new molecular targets that could be involved in predicting response and prognosis...